Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway

British Journal of Cancer

Volumn 107, Issue 10, 2012, Pages 1722-1728

  Joshi, H ^a   Bhanot, G ^b   Borresen Dale, A L ^c,d   Kristensen, V ^a,c,d  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; Dysregulated pathways; Estrogen receptor signalling; Survival; TP53 mutation status; Vascular endothelial growth factor signalling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; VASCULOTROPIN;

ARTICLE; BREAST CARCINOGENESIS; CALCIUM SIGNALING; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; KIDNEY CANCER; LUNG CANCER; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; UNIVARIATE ANALYSIS; UPREGULATION;

BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MUTATION; RECEPTORS, ESTROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84869083240     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.461     Document Type: Article

References (45)

1. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814. (Pubitemid 26225099)
2. Applanat MP, Buteau-Lozano H, Herve MA, Corpet A (2008) Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Biol 617: 437-444.
3. Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21: 1973-1979. (Pubitemid 46606386)
4. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, Van Staveren IL, Van Putten WL, Inganas M, Meijer-Van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG (2000) Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60: 2155-2162. (Pubitemid 30225178)
5. Berns EMJJ, Klijn JGM, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, Van Staveren IL, Meijer-Van Gelder ME, Bakker B, Sweep FCGJ, Foekens JA (2003) Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res 9: 1253-1258. (Pubitemid 36418374)
6. Bertheau P, Turpin E, Rickman DS, Espié M, De Reynie's A, Feugeas J-P, Plassa L-F, Soliman H, Varna M, De Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset J-L, Janin A, De Thé H (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4: 10.
7. Blandino G, Levine AJ, Oren M (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18(2): 477-485. (Pubitemid 29060623)
8. Børresen AL, Andersen TI, Eyfjörd JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S (1995) TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14: 71-75.
9. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M (2002) Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: A complex interplay between estrogen receptors alpha and beta. Cancer Res 62(17): 4977-4984. (Pubitemid 34984422)
10. D'Assoro AB, Leontovich A, Amato A, Ayers-Ringler JR, Quatraro C, Hafner K, Jenkins RB, Libra M, Ingle J, Stivala F, Galanis E, Salisbury JL (2010) Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. Int J Oncol 37: 1167-1176.
11. Dawson MI, Chao WR, Pine P, Jong L, Hobbs PD, Rudd CK, Quick TC, Niles RM, Zhang XK, Lombardo A (1995) Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res 55(19): 4446-4451.
12. Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Vanveldhuizen PJ, Banerjee SK (2008) Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res 68(12): 4580-4587.
13. Dinu I, Potter JD, Mueller T, Liu Q, Adewale AJ, Jhangri GS, Einecke G, Famulski KS, Halloran P, Yasui Y (2007) Improving gene set analysis of microarray data by SAM-GS. BMC Bioinformatics 8: 242.
14. Dittmer J (2003) The Biology of the Ets1 Proto-Oncogene. Mol Cancer 2: 29.
15. Enerly E, Steinfeld I, Kleivi K, Leivonen S-K, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale A-L (2011) miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors. PLoS One 6: 13.
16. Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M (2010) p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Int J Cancer 128(8): 1813-1821.
17. Gjoerup OV, Wu J, Chandler-Militello D, Williams GL, Zhao J, Schaffhausen B, Jat PS, Roberts TM (2007) Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc Natl Acad Sci USA 104: 8334-8339. (Pubitemid 47175488)
18. Goeman JJ, Van Houwelingen HC, Finos L (2011) Testing against a highdimensional alternative in the generalized linear model: Asymptotic type I error control. Biometrika 98: 381-390.
19. Han QX, Allegretto EA, Shao ZM, Kute TE, Ordonez J, Aisner SC, Rishi AK, Fontana JA (1997) Elevated expression of retinoic acid receptor-Alpha (RAR alpha) in estrogen-receptor-positive breast carcinomas as detected by immunohistochemistry. Am J Surg Pathol Part B 6(1): 42-48. (Pubitemid 27110985)
20. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1): 44-57.
21. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, Bork P, Von Mering C (2009) STRING 8 Y a global view on proteins and their functional interactions in 630. organisms. Nucl Acids Res 37: D412-D416.
22. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118-127. (Pubitemid 44906106)
23. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6: 50-56. (Pubitemid 30064975)
24. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28(1): 27-30. (Pubitemid 30047706)
25. Kim E, Deppert W (2006) The versatile interactions of p53 with DNA: when flexibility serves specificity. Cell Death Differ 13(6): 885-889.
26. Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Ka°resen R, Børresen-Dale A-L, Jeffrey SS (2007) TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9(3): R30.
27. Li S, Banck M, Mujtaba S, Zhou M-M, Sugrue MM, Walsh MJ (2010) p53-Induced Growth Arrest Is Regulated by the Mitochondrial SirT3. Deacetylase. PLoS One 5: 12.
28. Liang Y, Wu J, Stancel GM, Hyder SM (2005) p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. J Steroid Biochem Mol Biol 93(2-5): 173-182. (Pubitemid 40602490)
29. Liu Q, Dinu I, Adewale AJ, Potter JD, Yasui Y (2007) Comparative evaluation of gene-set analysis methods. BMC Bioinformatics 8: 431.
30. Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, Karuppayil SM, Rajasekaran AK, Das GM (2006) Estrogen receptor-Alpha binds p53. tumor suppressor protein directly and represses its function. J Biol Chem 281(15): 9837-9840. (Pubitemid 43864514)
31. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM (2000) Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 30-kinase and distinct from that induced by hypoxia. Cancer Res 60(20): 5879-5886.
32. Merico D (2009) Enrichment map: A network-based method for gene-set enrichment visualization and interpretation. PLoS One 5: e13984.
33. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102(38): 13550-13555. (Pubitemid 41420886)
34. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Ka°resen R, Nesland JM, Børresen-Dale A-L, Sørlie T (2007) Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 1(2): 160-171. (Pubitemid 47199130)
35. Norberg T, Klaar S, Kärf G, Nordgren H, Holmberg L, Bergh J (2001) Increased p53 mutation frequency during tumor progression Y results from a breast cancer cohort. Cancer Res 61: 8317-8321. (Pubitemid 33091627)
36. O'Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3): 20-29. (Pubitemid 43152727)
37. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bie'che I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale A-L (2006) The clinical value of somatic TP53. gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157-1167. (Pubitemid 43342504)
38. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J clin oncol 27(8): 1160-1167.
39. R Development Core Team (2011) R: A Language and Environment for Statistical Computing. Vienna Austria R Foundation for Statistical Computing 1: ISBN 3-900051-07-0.
40. Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, Massie CE, Vowler SL, Eldridge M, Carroll JS (2010) Cooperative interaction between retinoic acid receptor-Alpha and estrogen receptor in breast cancer. Genes Dev 24: 171-182.
41. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3.
42. Therneau T, Lumley T (2009) Survival: Survival Analysis Including Penalised Likelihood. R package Version 2.35-8. R package version 2.35-8. http://CRAN.R-project.org/package=survival.
43. Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, van Dam PA (2009) The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 100(6): 971-978.
44. Wyllie F, Haughton M, Bartek J, Rowson J, Wynford-Thomas D (2003) Mutant p53 can delay growth arrest and loss of CDK2 activity in senescing human fibroblasts without reducing p21(WAF1) expression. Exp Cell Res 285(2): 236-242. (Pubitemid 36428956)
45. Yang Y, Kort EJ, Ebrahimi N, Zhang Z, Teh BT (2010) Dual KS: defining gene sets with tissue set enrichment analysis. Cancer Inform 9: 1-9